RecruitingNCT07588880

A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in China

Studying Progressive familial intrahepatic cholestasis

Last synced from ClinicalTrials.gov May 18, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Ipsen
Principal Investigator: Ipsen Medical Director
Ipsen
Enrollment: 20 enrolled
Eligibility: All sexes
Timeline: 2026 – 2031

Study locations (1)

Children's Hospital of Fudan University Endocrinology and Metabolism, Shanghai, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07588880 on ClinicalTrials.gov

← Back to all trials